Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

Gilead Sciences said a combination of its cancer drug Trodelvy and Merck’s Keytruda delayed the growth of tumors in women ...

Gilead Sciences announced significant results from a Phase 3 study of Trodelvy combined with Merck's Keytruda in treating ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to ...

Gilead Sciences said that it saw positive results from the phase 3 study of its Trodelvy therapy in combination with Merck's Keytruda in patients with inoperable locally advanced or metastatic ...

Neoadjuvant combination immunotherapy may improve survival compared with single-agent therapy for patients with head and neck ...

Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.

Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back ...

As per the analyst, a significant driver of the positive outlook is KEYTRUDA, Merck & Co., Inc. (NYSE:MRK)’s blockbuster drug, which has supported it in establishing the company as a leader in ...

Oncology accounts for around 50% of Merck’s total revenues. Blockbuster PD-L1 inhibitor, Keytruda, approved for several types of cancers, alone accounts for around 50% of its pharmaceutical sales.

Cutaneous immune-related adverse events that develop after immune checkpoint inhibitor therapy become chronic in nearly ...